Nav: Home

Dolutegravir, an alternative first-line HIV treatment for low and middle-income countries

October 31, 2018

Conducted in Yaoundé (Cameroon), the study aims to compare the efficacy of two first-line treatments for HIV infection in more than 600 participants. The results of the trial, coordinated by Dr Charles Kouanfack (Yaoundé Central Hospital, Faculty of Medicine and Pharmaceutiques Sciences of Dschang University) and Pr Éric Delaporte (TransVIHMI, Montpellier University, Research and Development Institute (IRD) and French National Institute of Health and Medical Research (INSERM)), show that dolutegravir-based treatment is in not inferior to treatment with efavirenz (400 mg). In the specific context of treatment for people living with HIV in Southern countries, the researchers believe that first-line treatment with dolutegravir is a good alternative to efavirenz. The findings of the study, co-funded by Unitaid and ANRS, are being presented at the HIVDrugTherapy Conference in Glasgow on Wednesday, 31 October 2018.

The latest World Health Organization (WHO) recommendations published in July 2018, advocate first-line treatment of HIV infection using dolutegravir(1) (DTG) as an alternative to treatment with efavirenz 400 mg (EFV400)(2) . Until now, no clinical trial data have been collected to directly compare the efficacy of the two drugs in the specific context of low-income countries. The ANRS NAMSAL study has compared the effect of both DTG and EFV with 613 participants living with HIV who had not previously received ARV treatment.

According to Unitaid Deputy Executive Director Dr Philippe Duneton: "This trial is the first of its kind to supply comparative data on the use of dolutegravir in people living with HIV in low-income countries such as Cameroon. Unitaid values the great importance of the partnership with ANRS and WHO, because it will accelerate access to better HIV treatment."

The participants in the ANRS NAMSAL trial were randomly divided into two groups. The first group followed a DTG-based regimen, while the second followed a EFV400-based regimen. After 48 weeks, 74.5% of the DTG participants and 69% of the EFV400 participants presented with an HIV plasma viral load of below 50 copies per ml of blood.

This shows that DTG-based treatment is not inferior to EFV400-based treatment. The fact that dolutegravir is not inferior to efavirenz 400 has been demonstrated. The observed difference between the two treatments was not significant enough to assert the superiority of either regimen over the other. Moreover, participants showed similar tolerance to both treatments.DTG is thus considered a valid treatment option in first line in the context of treating people with HIV in low and middle-income countries.

According to Professor Éric Delaporte: "In patients presenting with a high viral load in their blood at the start of treatment, we observed persistently low viral replication rates in both prescribed treatments (DTG and EFV). Hence, it is important to continue long-term monitoring of the patients who initiated DTG treatment to confirm the absence of resistance mutations to this drug; the trial will continue until 2021".

"We welcome the results from this important research", said Dr Gottfried Hirnschall, WHO's Director for HIV and hepatitis. "The ANRS NAMSAL study supports joint efforts being made by WHO and Unitaid to optimize HIV treatment and to identify ever better and safer treatments for people living with HIV".

The ANRS New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-income countries (NAMSAL) trial launched in July 2016 is being conducted in Cameroon at three hospitals in Yaoundé: The Central Hospital, the Military Hospital and the Cité Verte district hospital. It will continue until 2021. It included more than 600 participants infected with HIV who had never had antiretroviral treatment. The aim was to compare the efficacy, tolerance and cost of the two first-line antiretroviral treatments, efavirenz 400 mg and dolutegravir. The trial is being promoted by ANRS and coordinated by Dr Charles Kouanfack (Faculty of Medicine and Pharmaceutiques Sciences of Dschang University) and Pr Éric Delaporte (TransVIHMI). It is co-funded by ANRS and Unitaid.
-end-
Sources:

Dolutegravir- versus an efavirenz 400mg-based regimen for the initial treatment of HIV-infected patients in Cameroon: 48-week efficacy results of the NAMSAL ANRS 12313 trial Amandine Cournil1, Charles Kouanfack2,3, Sabrina Eymard-Duvernay1, Serra Lem3, Mireille Mpoudi-Ngole4, Pierrette Omgba5, Serge Tchokonte2, Ginette Edoul Mbesse6, Eitel Mpoudi-Ngole4, Alexandra Calmy7, Eric Delaporte1,8, for the NAMSAL study group 1. TransVIHMI, Montpellier University, IRD, INSERM, Montpellier, France, 2. Central Hospital, Yaoundé, Cameroon, 3. ANRS, Yaoundé, Cameroon, 4. Military Hospital, Yaoundé, Cameroon, 5. Cité Verte Hospital, Yaoundé, Cameroon, 6. PreVIHMI International Joint Laboratory, IRD, CREMER, Yaoundé, Cameroon, 7. Geneva University Hospitals, Geneva, Switzerland, 8. University Teaching Hospital, Montpellier, France HIVDrugTherapy Conference, Glasgow Abstract available here: https://doi.org/10.1002/jia2.25187

(1) With a note of caution on the use of DTG in the periconception phase and for women and teenage girls of childbearing age, considering the possible risk of malformation of the neural tube when DTG is used during the first three months of pregnancy.

(2) EFV 400 is better tolerated than EFV 600, which is normally prescribed, and it is also available in fixed-dose combination tablets.

ANRS

Related Hiv Articles:

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).
Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.
Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.
The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.
The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.
Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.
NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
First ever living donor HIV-to-HIV kidney transplant
For the first time, a person living with HIV has donated a kidney to a transplant recipient also living with HIV.
The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.
Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.
More HIV News and HIV Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

TED Radio Wow-er
School's out, but many kids–and their parents–are still stuck at home. Let's keep learning together. Special guest Guy Raz joins Manoush for an hour packed with TED science lessons for everyone.
Now Playing: Science for the People

#565 The Great Wide Indoors
We're all spending a bit more time indoors this summer than we probably figured. But did you ever stop to think about why the places we live and work as designed the way they are? And how they could be designed better? We're talking with Emily Anthes about her new book "The Great Indoors: The Surprising Science of how Buildings Shape our Behavior, Health and Happiness".
Now Playing: Radiolab

The Third. A TED Talk.
Jad gives a TED talk about his life as a journalist and how Radiolab has evolved over the years. Here's how TED described it:How do you end a story? Host of Radiolab Jad Abumrad tells how his search for an answer led him home to the mountains of Tennessee, where he met an unexpected teacher: Dolly Parton.Jad Nicholas Abumrad is a Lebanese-American radio host, composer and producer. He is the founder of the syndicated public radio program Radiolab, which is broadcast on over 600 radio stations nationwide and is downloaded more than 120 million times a year as a podcast. He also created More Perfect, a podcast that tells the stories behind the Supreme Court's most famous decisions. And most recently, Dolly Parton's America, a nine-episode podcast exploring the life and times of the iconic country music star. Abumrad has received three Peabody Awards and was named a MacArthur Fellow in 2011.